PROTAGONIST THERAPEU

PTGX
Delayed Quote. Delayed  - 12/03 04:00:00 pm
32.27USD -1.28%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Other Biotechnology & Medical Research
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs fall under two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. Its other clinical assets PTG-943 and PTG-200, are orally delivered investigational drugs in development for inflammatory bowel disease (IBD) that are designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-235 and PN-232 are in clinical development, which are IL-R antagonists. Protagonist Pty Limited is its subsidiary.

Number of employees : 79 people.
Sales per Business
20192020
Peptide-based Therapeutics0.23100%28.63100%
USD in Million
Sales per region
20192020
United States0.23100%28.63100%
USD in Million
Managers
Name Title
Dinesh V. Patel President, Chief Executive Officer & Director
Donald A. Kalkofen Chief Financial Officer
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Scientific Officer
Samuel R. Saks Chief Medical Officer
Paula O’Connor Senior Vice President-Clinical Development
William D. Waddill Independent Director
Lewis T. Williams Independent Director
Sarah B. Noonberg Independent Director
Shareholders
Name Equities %
Fidelity Management & Research Co. LLC 5,714,586 12.0%
Point72 Asset Management LP 4,312,300 9.07%
BVF Partners LP 3,901,759 8.21%
Consonance Capital Management LP 3,446,874 7.25%
Johnson & Johnson Innovation JJDC, Inc. 2,449,183 5.15%
Farallon Capital Management LLC 2,392,000 5.03%
The Vanguard Group, Inc. 2,233,139 4.70%
SSgA Funds Management, Inc. 2,013,979 4.24%
RTW Investments LP 1,753,695 3.69%
Lilly Ventures Management Co. LLC 1,559,060 3.28%
Company contact information
Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
Suite 140
Newark, CA 94560-1160

Phone : +1.510.474.0170
Web : http://www.protagonist-inc.com
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.60.07%1 540
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.05%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-41.36%24 745
ICON PUBLIC LIMITED COMPANY40.04%22 226
ALNYLAM PHARMACEUTICALS, INC.38.44%21 869
PHARMARON BEIJING CO., LTD.46.38%20 688
ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.59.99%20 134
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.43.03%18 468
BIO-TECHNE CORPORATION47.15%18 362
HANGZHOU TIGERMED CONSULTING CO., LTD-15.72%17 493
PPD, INC.37.87%16 582
INCYTE CORPORATION-23.40%14 718
QIAGEN N.V.2.57%12 386
NOVAVAX, INC.72.76%12 246
PRA HEALTH SCIENCES, INC.0.00%10 965
GENSCRIPT BIOTECH CORPORATION247.52%10 631
SYNEOS HEALTH, INC.41.63%10 229
BACHEM HOLDING AG58.03%10 021
Brand Portfolio
» More brands of Protagonist Therapeutics, Inc.